Chemotherapy-Induced Cognitive Impairment in Women With Breast Cancer: A Critique of the Literature
ABSTRACT To review and critique the studies that have investigated chemotherapy-induced impairments in cognitive function in women with breast cancer.
Published research articles and textbooks.
Although studies of breast cancer survivors have found chemotherapy-induced impairments in multiple domains of cognitive function, they are beset with conceptual and methodologic problems. Findings regarding cognitive deficits in women with breast cancer who currently are receiving chemotherapy are even less clear.
Although data from published studies suggest that chemotherapy-induced impairments in cognitive function do occur in some women with breast cancer, differences in time since treatment, chemotherapy regimen, menopausal status, and neuropsychological tests used limit comparisons among the various studies. Further studies need to be done before definitive conclusions can be made.
The potential for chemotherapy-induced impairments in cognitive function may influence patients' ability to give informed consent, identify treatment toxicities, learn self-care measures, and perform self-care behaviors.
- SourceAvailable from: repositorio-aberto.up.pt
- [Show abstract] [Hide abstract]
ABSTRACT: To review what is known about survivorship issues for women after ovarian cancer treatment while identifying gaps and controversies. MEDLINE, CINAHL, and CancerLit database searches using the key words ovarian cancer, quality of life (QOL), chronic care, coping, uncertainty, and survivor separately and in combination. Data were categorized into psychosocial, QOL, and physical symptoms and reviewed for design, sample size, method, and outcome. Ovarian cancer studies focus on women's symptoms and concerns during treatment. Needs and issues of long-term survivors lack exploration. The relationship of ovarian cancer survivorship and physical side effects of treatment or recurrence is insufficient given increasing survival rates. The nature and management of physical symptoms, beyond pain, in ovarian cancer survivors need further study. Specifically, QOL and psychosocial issues for long-term survivors require study. Consequences for women who undergo major tissue debulking or multiple and aggressive courses of cytotoxic treatments must be understood to facilitate intervention.Oncology Nursing Forum 06/2006; 33(3):553-62. DOI:10.1188/06.ONF.553-562 · 1.91 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: The American Cancer Society (ACS) defines cancer survivorship as beginning at diagnosis with cancer and continuing for the balance of life and views quality of life (QOL) as a key outcome. In this article, the authors describe the rationale, methodology, and sample characteristics of the 2 ACS Studies of Cancer Survivors (SCS): 1) a longitudinal study identifying and surveying survivors approximately 1 year postdiagnosis that includes plans to resurvey the panel at 2 years, 7 years, and 12 years postdiagnosis to identify predictors of QOL; and 2) a cross-sectional study of QOL among 3 separate cohorts of survivors who were approximately 3 years, 6 years, and 11 years postdiagnosis at the time of data collection. Survivors of prostate, breast, lung, colorectal, bladder, skin, kidney, ovarian, and uterine cancers and of non-Hodgkin lymphoma were sampled from 25 different central cancer registries, with African-American and Hispanic survivors over sampled. Survivors completed either mail or telephone surveys that described their physical, psychological, social, and spiritual functioning. The overall recruitment rate was 34.0%; 15411 participants completed surveys, of whom 40.1% had a high school education or less and 19.4% were racial/ethnic minorities. The SCS surveys provide a large diagnostically, geographically, and demographically diverse database on cancer survivorship that was designed to overcome some of the limitations of past research. Future reports will compare QOL of survivors at different well-defined times postdiagnosis, investigate the issues of understudied populations and diagnostic groups, and describe survivor QOL at state levels. Insights valuable to those considering registry-based studies are offered on issues of ascertainment, sampling, and recruitment.Cancer 01/2007; 109(1):1-12. DOI:10.1002/cncr.22387 · 4.90 Impact Factor